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Objective: Epigallocatechin gallate (EGCG) inhibits glucose absorption into the blood by inhibiting small intestinal α-glucosidase but is unstable in 
gastric fluid. Hence, we formulated EGCG into enteric preparations that prevent release in gastric fluid.
Methods: Granules were prepared using a wet granulation method and were formulated into polyvinylpyrrolidone (PVP)-Eudragit L100-55 (5:1; F1), 
PVP-Eudragit L100-55 (1:1; F2), and Eudragit L100-55 (F3) preparations using 30% w/w Eudragit L100-55 as a matrix. EGCG contents of granules 
were evaluated and dissolution tests were performed at pH 1.2 and 6.8.
Results: F1–3 formulas had good flow properties and contained EGCG at 24.05%±0.15%–24.96%±0.28%. Dissolution tests showed that F1 and F2 
formulas released EGCG at 50.53%±0.04% and 17.80%±0.55%, respectively, after 2 h in HCl medium at pH 1.2. Cumulative drug release from F1 and 
F2 formulations after 2 h under these conditions (pH 1.2) and 1 h in phosphate buffer (pH 6.8) was 94.40%±1.58% and 93.70%±1.08%, respectively.
Conclusion: As the optimal formula, F3 granules limited drug release to 7.03%±0.22% in HCl at pH 1.2 over 2 h and cumulative drug release in HCl 
medium (pH 1.2) followed by phosphate buffer (pH 6.8) of 86.13%±0.20%.
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INTRODUCTION
Epigallocatechin gallate (EGCG) is a major active compound in green tea 
and reportedly inhibits dietary glucose absorption into the blood. The 
previous studies show that EGCG inhibits intestinal α-glucosidases [1]. 
Accordingly, in vivo experiments showed that 100 mg of EGCG 
significantly reduced post-prandial blood glucose levels in rats fed on 
corn starch [2]. EGCG is known to be sensitive to acid degradation and 
hydrolysis in gastric fluids [3] and hence lacks gastrointestinal stability. 
EGCG is, however, stable at pH 4–6 [4] and degradation of EGCG in 
gastric acid can be prevented by enteric formulations.
Enteric coat technology is commonly used to develop delayed release 
systems for drug preparations. These limit drug release in the stomach 
and favor rapid release in the intestine [5]. Manufacture of enteric-
coated preparations requires several stages and is time-consuming [6], 
warranting the development of alternative pH-sensitive enteric matrixes.
In this study, the matrix granules Eudragit L100-55 and 
polyvinylpyrrolidone (PVP) were used in combination. Recent 
experiments show that Eudragit L100-55 can prohibit drug release to 
<10% in HCl medium of pH 1.2 at a minimum concentration of 5% [7]. 
Eudragit L100-55 is a methacrylate copolymer that resists drug release 
in the stomach and prioritizes release in the intestine [8]. Dissolution 
profiles at various pH values are strongly correlated with the performance 
of such enteric polymers. Eudragit L100-55 polymer releases its contents 
at the small intestinal pH of >5.5, where α-glucosidase enzyme is located. 
PVP is a hydrophilic polymer that can be used to control and increase 
drug release, and also acts as a binder [9]. Thus, in this study, PVP-
Eudragit L100-55 combinations were expected to increase drug release 
in the small intestine. With the expectation that polymer controlled drug 
release systems can regulate the release of EGCG into the small intestine, 
we generated enteric green tea leaf extract granules containing EGCG 
using Eudragit L100-55 as a delayed-release matrix polymer.
MATERIALS AND METHODS
Materials
Green tea leaf (Camellia sinensis) extract (AndyBiotech, China), EGCG 
(Sigma Aldrich, Singapore), Eudragit L 100-55 (Evonik, Germany), PVP 
(Nanhang Industrial Co., China), Avicel pH 101 (AIC, USA), acetonitrile 
(Merck, Germany), HCl (Brand, Germany), glacial acetic acid (Merck, 
Germany), potassium dihydrogen phosphate (Merck, Germany), methanol 
for LC (Merck, Germany), 96% ethanol (Brataco, Indonesia), aqua 
pro injection (IKAPHARMINDO, Indonesia), and aqua demineralisata 
(Brataco, Indonesia) were purchased from the parenthetic manufacturers.
Methods
Optimization of total polymer concentrations
Total polymer concentrations were optimized to withstand drug release 
in acidic medium. Polymer concentrations of 5%, 15%, and 30% were 
used with reference to previous research [7,10]. Granule formulas are 
listed in Table 1.
Granules were prepared using a wet granulation method. Briefly, green 
tea leaf extract, Avicel pH 101, and Eudragit L100-55 were combined to 
a total of 100 g and were mixed until a homogenous color was obtained. 
Wet granulation was then performed by adding up to 40 mL of 96% 
ethanol to obtain wet masses that could be clenched. Wet masses were 
then formed into granules using an eight mesh sieve. Moist granules 
were dried in an oven at 40±0.5°C for 2 h and were then reduced to 
desired sizes using an 18 mesh sieve.
Optimization of polymer concentrations
Visual tests
Granule samples of 300 mg with polymer concentrations of 5% (fumaric 
acid), 15% (FB), or 30% (FC) were placed in 150 mL glass beakers 
containing 100 mL of HCl media at pH 1.2 for 2 h. Intact granules were 
then tested for dissolution.
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Dissolution tests
Dissolution tests were performed as described previously [11,12] 
with various modifications. Representative gastric and duodenal 
fluids were produced in 100-mL aliquots using HCl (pH 1.2) and 
phosphate buffer (pH 6.8), respectively. After preparation in 
150-mL glass beakers, HCl media at pH 1.2 were added to 1000-mL 
glass beakers containing 200 mL of water and were then heated on a 
hot plate to 37±0.5°C. Granule samples of 260 mg containing 65 mg 
of EGCG were placed in 2 cm×2-cm bags made of filter paper sewn 
with mattress thread. Bags were then placed an acid medium at 
37±0.5°C and were stirred at 100 rpm using a magnetic stirrer. After 
2 h, 2-mL aliquots were transferred to 100 mL of phosphate buffer 
(pH 6.8) at 37±0.5°C and were stirred at 100 rpm. After 15, 30, 45, 
and 60 min, 2-mL aliquots of buffer media were taken and replaced 
with phosphate buffer pH 6.8. Dissolved EGCG contents of phosphate 
buffer samples were then determined using high-performance liquid 
chromatography (HPLC).
Formulation of granules
Enteric granule formulae of green tea leaf extracts are listed in Table 2. 
Granules containing green tea leaf extract, Avicel pH 101 (as a filler), 
Eudragit L100-55, and PVP in the relative quantities listed in Table 2 
were synthesized using the wet granulation method as described above.
Evaluation of enteric granules of green tea leaf extract
Organoleptic tests
Organoleptic tests included observations of shape, color, odor, and taste 
of the produced granules [13].
Granule size distribution tests
Size distributions of the granules were evaluated using sieve shakers. 
Briefly, series of five sieves with numbers 16, 25, 35, 45, and 60 were 
arranged in descending order from the largest sieve hole. Subsequently, 
25-g granule samples were placed in the top sieve and the sieving 
machine was run for 10 min. Weights of fractions remaining in the 
sieves were recorded as described previously [14].
Flow properties
Angle of repose
Test samples of 100 mL were introduced into dry funnels with nozzles 
of 10 mm in diameter. The angle of repose was determined according 
to the United States pharmacopeia 35. Specifically, an integrated driven 
laser of the Flow Tester was directed to the sidewall of the built-up cone 
and actual angles were calculated [14].
Calculation of compressibility indexes and Hausner ratios
Compressibility index values and Hausner ratios were calculated 
according to the United States pharmacopeia 35 equations using 
apparent density data and tapped density tests. The results are shown 
in Table 3.
Determination of EGCG levels in granules
Instrumentation and operation conditions for HPLC
EGCG concentrations were determined using a Shimadzu HPLC column 
model LC6A with a SPD-6AV UV-visible detector and a Kromasil column 
100–5 C18 of 250 mm×4.6 mm. Samples of 20 µL were injected and 
eluted using a mobile phase comprising 0.05% acetic acid-acetonitrile 
(87:13 v/v) with a final pH of 3.5–4 and with a column temperature 
of 20±3°C and a flow velocity of 1 mL/min. Elutes were detected at a 
wavelength of 280 nm [15].
Determination of EGCG levels in granules
Granule samples of 1 g were grinded to obtain powder, of which 50-
mg aliquots were diluted to 25 mL in volumetric flasks. Solutions were 
sonicated for 5 min, were filtered through Millipore filters to remove 
particles, and were then injected into the HPLC instrument. Tests were 
performed in triplicate and EGCG concentrations were calculated 
by entering measured areas under the curve into linear regression 
equations.
Dissolution tests
Dissolution tests were performed as described for optimization of total 
polymer concentrations in granule formulations.
RESULTS AND DISCUSSION
Optimization of total polymer concentrations in formulas
After treating granules in acid medium for 2 h, visual optimization 
observations showed that enteric granule matrixes containing polymer 
at 5% formed unfavorable soft masses at the bottoms of the containers 
(Fig. 1). Yet at polymer concentrations of 15% and 30%, granule shapes 
remained and did not become soft.
Formulas B (Eudragit L100-55 15%) and C (Eudragit L100-5 30%) were 
then tested for dissolution in HCl at pH 1.2 over 2 h. Formula B released 
24.03%±2.28% of the active substance under these conditions, whereas 
formula C (30% Eudragit L100-55) released only 7.03%±0.22% of 
active substance. Based on the results of these preliminary tests, the 
optimal polymer concentration for resisting the release of active 
substance into acid medium was 30%.
To improve on 30% Eudragit L100-55 matrixes, we produced F1–3 
formulas with PVP–Eudragit L100-55 ratios of 5:1, 1:1, and 0:1, 
respectively. The best of these formulas was used as the enteric 
preparation in dissolution tests.
Table 1: Granule formulas for optimization of enteric polymer 
concentrations
Material FA (%) FB (%) FC (%)
Green tea leaf extract 50 50 50
Avicel pH 101 45 35 20
Eudragit L 100-55 5 15 30
Total 100 100 100




Green tea leaf extract (contains 50% EGCG) 50 50 50
Avicel pH 20 20 20
Eudragit L100-55 - - 30
PVP-Eudragit L 100-55 (1:1) - 30 -
PVP-Eudragit L 100-55 (5:1) 30 - -
EGCG: Epigallocatechin gallate, PVP: Polyvinylpyrrolidone
Table 4: Cumulative epigallocatechin gallate release
Formula Cumulative drug 
release in HCl medium 
at pH 1.2; mean±SD (%)
Cumulative drug release in 
HCl medium at pH 1.2 and 













1 4.37±0.07 32.52±0.41 12.25±0.07 1.14±0.00
2 4.12±0.03 33.00±0.37 12.70±1.37 1.14±0.01
3 4.20±0.02 32.43±0.16 12.09±0.05 1.13±0.00
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Formulation of granules
Following manufacture with 100-g mixtures, F1–3 granules were 
yielded at 92.82, 91.52, and 90.45 g, respectively. The 8%–10% losses in 
mass reflect residues left in containers and sieves during manufacture.
Evaluation of granule masses
Organoleptic tests
The three granule formulas described herein had single large granular 
solid forms, were brownish-orange in color and had a green tea flavor 
with a slightly bitter taste.
Particle size distribution tests
Particle size distributions of F1–F3 granules were measured using 
multilevel sieves covering the range 0–1180 µm. The results of tests 
with 710–1180-μm sieves are shown in Fig. 2.
Particle size distribution tests ensure uniformity of contact surface 
areas with dissolution medium during dissolution testing, thus 
facilitating comparisons of granules.
Tests of flow properties
As shown in Table 3, flowabilities of granules were tested using various 
methods and properties of the formulations were characterized as 
precisely as possible. To identify differences in flow characteristics of 
the granules, we measured of angles of repose, performed flowability 
tests, and determined compressibility indexes and Hausner ratios.
The values for angles of repose, compressibility index, and Hausner 
ratios were similar for all granules (Table 3). Moreover, all prepared 
formulations had good flow properties, with angles of repose within 
31°–35°, compressibility indexes of 11%–15%, and Hausner ratios of 
1.12–1.18.
Determination of EGCG levels in granules
EGCG levels were determined by grinding 1 g of granules and then 
diluting 50-mg samples (equivalent to 12.5 mg EGCG) in 25 mL of mobile 
phase. EGCG contents of F1–3 preparations were 24.05%±0.15%, 
24.78%±0.14%, and 24.96%±0.28%, respectively.
Dissolution test
To evaluate drug release profiles from granules, we set up calibration 
curves of EGCG standard solutions in acid (pH 1.2) and phosphate 
buffer (pH 6.8). These gave linear concentration curves following the 
equations y=21626x+103950 (r=0.9998) and y=20691x–128135 
(r=0.9999), respectively.
Dissolution profiles of granules from F1–3 preparations in acid for 2 h 
followed by phosphate buffer for up to 60 min are shown in Fig. 3.
The dissolution profiles of EGCG in Fig. 3 show that F1 and F2 granules 
containing green tea leaf extracts failed to prevent release of the drug 
in acidic medium, releasing 50.53%±0.04% and 17.80%±0.55% of 
active compound, respectively. In contrast, the F3 formula comprising 
Eudragit L100-55 at 30% cumulatively released only 7.03%±0.22% of 
the active compound over 2 h in an acid medium.
Addition of PVP at 5 times, the concentration of Eudragit L100-55 (5:1) 
led to greater release of the drug in acid medium over 2 h. These 
observations can be explained by the predominance of PVP over Eudragit 
L100-55 as the matrix constituent polymer. Under these conditions, 
the matrix was eroded in acidic medium because PVP polymers are 
pH-sensitive, although PVP can act as a binder [9]. In F2 preparations, 
the percentage of drug release in acid media was smaller than from 
F1 preparations. Thus, additional Eudragit L100-55 concentrations in 
the matrix can reduce drug release in acid medium. F2 was better able 
to withstand drug release in acidic medium than F1, although it still 
released >10% of the active compound. These results show that 5:1 and 
1:1 combinations of PVP and Eudragit L100-55 in granule matrixes are 
not optimal for preventing drug release in acid medium over 2 h. The 
granules with a matrix consisting of 30% Eudragit L100-55 are at least 
released from the granules at ph 2.
Cumulative drug release from F1 and F2 preparations was higher 
than from F3, as shown in Table 4. Similarly, previous research [7,10] 
showed that higher Eudragit L100-55 concentrations in the formula 
reduce dissolution rates. Accordingly, at low pH, Eudragit L100-55 
does not dissolve and drug release is regulated by diffusion of the 
active substance from the matrix. At higher pH, drug release is affected 
Fig. 2: Particle size distribution curves of granule formulas 
containing green tea leaf extract; Data are presented as 
means±standard deviations (n=3)
Fig. 3: Epigallocatechin gallate dissolution profiles of F1–3 
formulations containing green tea leaf extract; tests were 
performed in HCl (pH 1.2) for 2 h followed by phosphate buffer 
(pH 6.8) for up to 60 min. Data are presented as means±SD; n=3
Fig. 1: (a) Fumaric acid FA, granules with 5% Eudragit; (b) FB, 
granules with 15% Eudragit; (c) FC, granules with 30% Eudragit; 
after incubation in acid medium for 2 h
cba
Int J App Pharm, Vol 12, Special Issue 1, 2020
 Anwar and Sherman 
 The 4th International Conference on Global Health 2019 129
by Eudragit L100-55 polymer solubilization and degradation of the 
matrix [10]. Therefore, higher Eudragit L100-55 concentrations in F3 
likely require longer dissolution times to achieve the same cumulative 
release as from the Eudragit L100-55 formulas F1 and F2.
CONCLUSION
Enteric granules formulated with 30% w/w Eudragit L100-55 as a 
matrix polymer released only 7.03%±0.22% of their drug contents in 
acidic medium over 2 h but cumulatively released 86.13%±0.20% of 
drug contents after a further hour in phosphate buffer at pH 6.8.
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